Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements study discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://marcellef825ucj8.wikitelevisions.com/user